Genetic determinants of childhood leukemia;Les déterminants génétiques de la leucémie de l'enfant

Bulletin du Cancer

Volumn 93, Issue 9, 2006, Pages 857-865

  Sinnett, Daniel ^a   N'Diaye, Nina ^a   Labuda, Damian ^a   Krajinovic, Maja ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Complex disease; Folate; Leukemia; Metabolism of carcinogens; Oncogenetics; Parental genetics; Pediatric cancer; Polymorphism

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; DNA POLYMORPHISM; DNA REPAIR; DNA REPLICATION; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; LEUKEMIA; LEUKEMOGENESIS; OXIDATIVE STRESS; PREVALENCE; REVIEW; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; CHILD; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; METABOLISM;

CARCINOGEN; CYTOCHROME P450; FOLIC ACID; GLUTATHIONE TRANSFERASE;

ADOLESCENT; CARCINOGENS; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; ENVIRONMENT; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MATERNAL EXPOSURE; OXIDATIVE STRESS; PATERNAL EXPOSURE;

EID: 33749075191     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Stiller CA. Epidemiology and genetics of childhood cancer. Oncogene 2004; 23: 6429-44.
2. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999; 93: 1496-501.
3. Sinnett D, Krajinovic M, Labuda D. Genetic susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma 2000; 38: 447-62.
4. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991; 4: 391-407.
5. Daly AK, Fairbrother KS, Smart J. Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Toxicol Lett 1998; 102-103: 143-7.
6. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 1995; 87: 902-7.
7. Shields PG. Pharmacogenetics: detecting sensitive populations. Environ Health Perspect 1994; 102 (Suppl 11): 81-7.
8. Watanabe J, Hayashi S, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J Biochem (Tokyo) 1994; 116: 321-6; (Tokyo).
9. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 2002; 97: 230-6.
10. Powell H, Kitteringham NR, Pirmohamed M, Smith DA, Park BK. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 1998; 8: 411-21.
11. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
12. Ketterer B, Harris JM, Talaska G, et al. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 1992; 98: 87-94.
13. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997; 6: 733-43.
14. Cossar D, Bell J, Strange R, Jones M, Sandison A, Hume R. The alpha and pi isoenzymes of glutathione S-transferase in human fetal lung: in utero ontogeny compared with differentiation in lung organ culture. Biochim Biophys Acta 1990; 1037: 221-6.
15. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18: 641-4.
16. Hu X, Xia H, Srivastava SK, et al. Activity of four allelic forms of glutathione S-transferase hGSTP1-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 1997; 238: 397-402.
17. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997; 89: 1701-7.
18. Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK, Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994; 15: 1077-81.
19. Krajinovic M, Labuda D, Sinnett D. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics 2002; 12: 655-8.
20. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-80.
21. Hiley C, Bell J, Hume R, Strange R. Differential expression of alpha and pi isoenzymes of glutathione S-transferase in developing human kidney. Biochim Biophys Acta 1989; 990: 321-4.
22. Kettle AJ, Winterbourn CC. Oxidation of hydroquinone by myeloperoxidase. Mechanism of stimulation by benzoquinone. J Biol Chem 1992; 267: 8319-24.
23. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An All element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996; 271: 14412-20.
24. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997; 90: 2730-7.
25. Cascorbi I, Henning S, Brockmoller J, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant: 463A of the myeloperoxidase gene. Cancer Res 2000; 60: 644-9.
26. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997; 75: 69-75.
27. Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leedet JS. NAD(P)H: quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 1998; 8: 305-13.
28. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C → T polymorphism in the NAD(P)H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94: 803-7.
29. Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF. A lack of a functional NAD(P)H: quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res 1999; 59: 4095-9.
30. Kim YI. Methylenetetrahydrofolate reductase polymorphisms, folate, and cancer risk: a paradigm of gene-nutrient interactions in carcinogenesis. Nutr Rev 2000; 58: 205-9.
31. Robien K, Ulrich CM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003; 157: 571-82.
32. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
33. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
34. Weisberg IS, Jacques PF, Selhub J, et al. The 1298A → C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001; 156: 409-15.
35. Krajinovic M, Lamothe S, Labuda D, et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2004; 103: 252-7.
36. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999; 96: 12810-5.
37. Wiemels JL, Smith RN, Taylor GM, Ede OB, Alexander FE, Greaves MF. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 2001; 98: 4004-9.
38. Kihara M, Noda K. Lung cancer risk of the GSTM1 null genotype is enhanced in the presence of the GSTP1 mutated genotype in male Japanese smokers. Cancer Lett 1999; 137: 53-60.
39. Fairbrother KS, Grove J, de Waziers I, et al. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998; 8: 543-52.
40. Ross D, Siegel D, Schattenberg DG, Sun XM, Moran JL. Cell-specific activation and detoxification of benzene metabolites in mouse and human bone marrow: identification of target cells and a potential role for modulation of apoptosis in benzene toxicity. Environ Health Perspect 1996; 104 (Suppl 6): 1177-82.
41. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997; 57: 5001-3.
42. Smith MT. Benzene, NQO1, and genetic susceptibility to cancer. Proc Natl Acad Sci USA 1999; 96: 7624-6.
43. Whyatt RM, Perera FP. Application of biologic markers to studies of environmental risks in children and the developing fetus. Environ Health Perspect 1995; 103 (Suppl 6): 105-10.
44. Thompson JR, Gerald PF, Willoughby ML, Armstrong BK. Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case-control study. Lancet 2001; 358: 1935-40.
45. Krajinovic M, Robaey P, Chiasson S, et al. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood. Pharmacogenomics 2005; 6: 293-307.
46. Infante-Rivard C, Sinnett D. Preconceptional paternal exposure to pesticides and increased risk of childhood leukaemia. Lancet 1999; 354: 1819.
47. Labuda D, Krajinovic M, Sabbagh A, Infante-Rivard C, Sinnett D. Parental genotypes in the risk of a complex disease. Am J Hum Genet 2002; 71: 193-7.
48. Infante-Rivard C, Krajinovic M, Labuda D, Sinnett D. Childhood acute lymphoblastic leukemia associated with parental alcohol consumption and carcinogen-metabolizing genetic polymorphisms. Epidemiology 2002; 13: 277-81.
49. Infante-Rivard C, Labuda D, Krajinovic M, Sinnett D. Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms. Epidemiology 1999; 10: 481-7.
50. Hakkola J, Pelkonen O, Pasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 1998; 28: 35-72.
51. Juchau MR. Drug biotransformation in the placenta. Pharmacol Ther 1980; 8: 501-24.
52. Manchester DK, Jacoby EH. Sensitivity of human placental monooxygenase activity to maternal smoking. Clin Pharmacol Ther 1981; 30: 687-92.
53. Kim YI. Folate and cancer prevention: a new medical application of folate beyond hyperhomocysteinemia and neural tube defects. Nutr Rev 1999; 57: 314-21.
54. Blount BC, Mack MM, Wehr CM, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997; 94: 3290-5.
55. Clavel J, Bellec S, Rebouissou S, et al. Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. Eur J Cancer Prev 2005; 14: 531-40.
56. Infante-Rivard C, Krajinovic M, Labuda D, Sinnett D. Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Quebec, Canada). Cancer Causes Control 2000; 11: 547-53.
57. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 2004; 43: 560-7.
58. Infante-Rivard C, Amre D, Sinnett D. GSTT1 and CYP2E1 polymorphisms and trihalomethanes in drinking water: effect on childhood leukemia. Environ Health Perspect 2002; 110: 591-3.
59. Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, Ozbek U. Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol 2006; 81: 162-70.
60. Pakakasama S, Mukda E, Sasanakul W, et al. Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia. Am J Hematol 2005; 79: 202-5.
61. Wang J, Zhang L, Feng J, Wang H, Zhu S, Hu Y. Genetic polymorphisms analysis of glutathion S-transferase M1 and T1 in children with acute lymphoblastic leukemia. J Huazhong Univ Sci Technolog Med Sci 2004; 24: 243-4.
62. Canalle R, Burim RV, Tone LG, Takahashi CS. Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen 2004; 43: 100-9.
63. Franco RF, Simoes BP, Tone LG, Gabellini SM, Zago MA, Falcao RP. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol 2001; 115: 616-8.
64. Zanrosso CW, Hatagima A, Emerenciano M, et al. The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population. Leuk Res 2006; 30: 477-81.
65. Chatzidakis K, Goulas A, Athanassiadou-Piperopoulou F, Fidani L, Koliouskas D, Mirtsou V. Methylenetetrahydrofolate reductase C677T polymorphism: Association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients. Pediatr Blood Cancer 2006; 47: 147-51.